Literature DB >> 28123260

Musculoskeletal oncogenic osteomalacia-An experience from a single centre in South India.

Anil Satyaraddi1, Kripa Elizabeth Cherian1, Sahana Shetty1, Nitin Kapoor1, Felix K Jebasingh1, Vinoo Mathew Cherian2, Julie Hephzibah3, Anne Jennifer Prabhu4, Nihal Thomas1, Thomas V Paul1.   

Abstract

BACKGROUND: Oncogenic osteomalacia is an acquired form of hypophosphatemic osteomalacia where the tumour resection may lead to cure of the disease. Tumours originating from the musculoskeletal region form an important subgroup of oncogenic osteomalacia.
METHODS: This was a retrospective study conducted at a tertiary care centre in south India where we analyzed the hospital records of all the patients with musculoskeletal oncogenic osteomalacia from January 2010-April 2016.
RESULTS: A total number of 73 patients were diagnosed to have adult onset hypophosphatemic osteomalacia out of which 13 patients (M: F = 6:7; mean age: 45.38 ± 18.23 years) with musculoskeletal oncogenic osteomalacia were included in the study. Common presenting symptoms were bony pains, proximal myopathy and fractures. Mean duration of symptoms from the initial hospital visit was 58.46 ± 64.48 months. The initial mean fibroblast growth factor (FGF) 23 levels being 828.86 ± 113.22 RU/ml (Normal range: 22-91). Imaging modalities used for localization of the tumour: DOTATATE PET/CT (8 patients), FDG PET/CT (3 patients), 1 patient (Both DOTATATE PET/CT and FDG PET/CT) and whole body Tc 99 m Red blood cell (RBC) blood pool scintigraphy (2 patients). 9 patients underwent surgery and all achieved remission. 4 patients denied surgical consent.
CONCLUSION: Musculoskeletal oncogenic osteomalacia is a major subgroup of oncogenic osteomalacia which need more extensive whole body imaging for the localization of the tumour. Surgical excision often leads to remission of the disease.

Entities:  

Keywords:  Fibroblast growth factor −23; Hypophosphatemia; Mesenchymal tumour; Oncogenic osteomalacia

Year:  2017        PMID: 28123260      PMCID: PMC5222952          DOI: 10.1016/j.jor.2016.12.010

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  14 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature.

Authors:  Yan Jiang; Wei-bo Xia; Xiao-ping Xing; Barbara C Silva; Mei Li; Ou Wang; Hua-bing Zhang; Fang Li; Hong-li Jing; Ding-romg Zhong; Jin Jin; Peng Gao; Lian Zhou; Fang Qi; Wei Yu; John P Bilezikian; Xun-wu Meng
Journal:  J Bone Miner Res       Date:  2012-09       Impact factor: 6.741

3.  The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.

Authors:  K E White; K B Jonsson; G Carn; G Hampson; T D Spector; M Mannstadt; B Lorenz-Depiereux; A Miyauchi; I M Yang; O Ljunggren; T Meitinger; T M Strom; H Jüppner; M J Econs
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Localisation of mesenchymal tumours by somatostatin receptor imaging.

Authors:  Suzanne M Jan de Beur; Elizabeth A Streeten; A Cahid Civelek; Edward F McCarthy; Liliana Uribe; Stephen J Marx; Olufunmilayo Onobrakpeya; Lawrence G Raisz; Nelson B Watts; Michael Sharon; Michael A Levine
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

Review 5.  "Phosphatonins" and the regulation of phosphorus homeostasis.

Authors:  Theresa J Berndt; Susan Schiavi; Rajiv Kumar
Journal:  Am J Physiol Renal Physiol       Date:  2005-12

6.  Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients.

Authors:  Swati Jadhav; Rajeev Kasaliwal; Vikram Lele; Venkatesh Rangarajan; Piyush Chandra; Hina Shah; Gaurav Malhotra; Varsha S Jagtap; Sweta Budyal; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-12       Impact factor: 3.478

7.  Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.

Authors:  Kanhaiyalal Agrawal; Sanjay Bhadada; Bhagwant Rai Mittal; Jaya Shukla; Ashwani Sood; Anish Bhattacharya; Anil Bhansali
Journal:  Clin Nucl Med       Date:  2015-01       Impact factor: 7.794

8.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

9.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

Review 10.  Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.

Authors:  Fang-Ke Hu; Fang Yuan; Cheng-Ying Jiang; Da-Wei Lv; Bei-Bei Mao; Qiang Zhang; Zeng-Qiang Yuan; Yan Wang
Journal:  Chin J Cancer       Date:  2011-11
View more
  7 in total

1.  Treating osteoporosis: a near miss in an unusual case of FGF-23 mediated bone loss.

Authors:  Jinson Paul; Kripa Elizabeth Cherian; Nitin Kapoor; Thomas Vizhalil Paul
Journal:  BMJ Case Rep       Date:  2019-03-16

2.  Ovarian Teratoma Causing Oncogenic Osteomalacia: An Instance of Serendipity.

Authors:  Jinson Paul; Antresa Jose; Beena Kingsbury; Marie Therese Manipadam; Nitin Kapoor; Thomas Vizhalil Paul; Kripa Elizabeth Cherian
Journal:  J Obstet Gynaecol India       Date:  2022-01-23

3.  Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.

Authors:  Yuanyuan Jiang; Guozhu Hou; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2020-04       Impact factor: 1.698

Review 4.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18

5.  Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study.

Authors:  Guozhu Hou; Yuwei Zhang; Yu Liu; Peipei Wang; Weibo Xia; Xiaoping Xing; Li Huo; Fang Li; Hongli Jing
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

6.  Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature.

Authors:  Zaina Adnan; David Nikomarov; Michal Weiler-Sagie; Noga Roguin Maor
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-05-03

Review 7.  Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis.

Authors:  Marie Meyer; Marie Nicod Lalonde; Nathalie Testart; Mario Jreige; Christel Kamani; Sarah Boughdad; Barbara Muoio; Fabio Becce; Niklaus Schaefer; Christian Candrian; Luca Giovanella; John O Prior; Giorgio Treglia; Martin Riegger
Journal:  Diagnostics (Basel)       Date:  2019-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.